Lowest-Rated StocksLowest-RatedNASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $5.68 +0.12 (+2.06%) As of 10:23 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RxSight Stock (NASDAQ:RXST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RxSight alerts:Sign Up Key Stats Today's Range$5.38▼$5.7250-Day Range$4.59▼$6.3552-Week Range$4.48▼$13.22Volume71,092 shsAverage Volume978,895 shsMarket Capitalization$235.36 millionP/E RatioN/ADividend YieldN/APrice Target$8.89Consensus RatingReduce Company Overview RxSight, Inc. is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction. Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. The company obtained CE marking in Europe for its LAL technology and later secured U.S. Food and Drug Administration approval for its second‐generation device in October 2020. Since then, RxSight has partnered with leading ophthalmology centers to integrate the LAL system into clinical practice, building a network of implantation sites throughout North America and preparing for broader global expansion under existing regulatory frameworks. In addition to its core LAL offering, RxSight continues to invest in research and development aimed at enhancing its lens portfolio and refining adjustment protocols. The company collaborates with ophthalmic surgeons and research institutions to advance surgical workflows and patient education initiatives. Under the leadership of President and Chief Executive Officer Steve McKnight, RxSight is committed to driving innovation in presbyopia correction and setting new standards for patient-centric eye care solutions.AI Generated. May Contain Errors. Read More RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 55% of companies evaluated by MarketBeat, and ranked 473rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingReduce Consensus RatingRxSight has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on no strong buy ratings, 2 buy ratings, 7 hold ratings, and 3 sell ratings.Upside PotentialRxSight has a consensus price target of $8.89, representing about 56.4% upside from its current price of $5.69.Amount of Analyst CoverageRxSight has only been the subject of 4 research reports in the past 90 days.Read more about RxSight's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($1.41) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -5.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.81% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 3.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently increased by 31.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment0.74 News SentimentRxSight has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for RxSight this week, compared to 8 articles on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have not sold or bought any company stock.Percentage Held by Insiders10.05% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXST Stock News HeadlinesRxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical OfficerJuly 15 at 4:15 PM | globenewswire.comPiper Sandler Keeps Their Hold Rating on RxSight (RXST)July 11, 2026 | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 17 at 1:00 AM | InvestorPlace (Ad)Wells Fargo Sticks to Its Hold Rating for RxSight (RXST)July 11, 2026 | theglobeandmail.comRxSight: After Dropping To The Bottom, It's Time To Pick It UpJuly 10, 2026 | seekingalpha.comGlancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of InvestorsJuly 10, 2026 | businesswire.comLaw Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of InvestorsJuly 8, 2026 | tmcnet.comThe Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of InvestorsJuly 7, 2026 | businesswire.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $10.42 on January 1st, 2026. Since then, RXST stock has decreased by 45.4% and is now trading at $5.6850. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) issued its quarterly earnings results on Wednesday, November, 5th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.15. The company's quarterly revenue was down 31.4% compared to the same quarter last year. Read the conference call transcript. When did RxSight IPO? RxSight (RXST) raised $125 million in an IPO on Wednesday, July 28th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings11/05/2025Today7/17/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 RXST's financial health is in the Red zone, according to TradeSmith. RXST has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year Founded1997Price Target and Rating Average Price Target for RxSight$8.89 High Price Target$11.00 Low Price Target$6.50 Potential Upside/Downside+64.9%Consensus RatingReduce Rating Score (0-4)1.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.94 million Net Margins-36.58% Pretax Margin-36.54% Return on Equity-17.01% Return on Assets-15.12% Debt Debt-to-Equity RatioN/A Current Ratio10.20 Quick Ratio8.93 Sales & Book Value Annual Sales$134.48 million Price / Sales1.66 Cash FlowN/A Price / Cash FlowN/A Book Value$6.70 per share Price / Book0.80Miscellaneous Outstanding Shares41,400,000Free Float37,237,000Market Cap$223.23 million OptionableOptionable Beta1.15 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:RXST) was last updated on 7/17/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
